hb-101
Vaccineexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2016 (NCT02798692)
Timeline
Indications
Mechanism of action
- CytomegalovirusImmunity, active
Cytomegalovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hb-101
- low dose hb-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03629080 | Phase 2 | Oct 15, 2018 | Hookipa Biotech |
| NCT02798692 | Phase 1 | Jun 1, 2016 | Ghent University, Hookipa Biotech, Universitair Ziekenhuis Gent |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hookipa Biotech | For profit | 2 | 2 | 2 | 2016 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Universitair Ziekenhuis Gent | Academic/Hospital | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1